Takeda Pharmaceutical Company Limited
4502・Prime Market・Pharmaceuticals
Business
Takeda Pharmaceutical Company Limited was founded in 1781 and has a 245-year history, making it one of Japan's largest global biopharmaceutical companies. It operates a group structure of 165 companies, including 154 consolidated subsidiaries, selling pharmaceuticals in approximately 80 countries and regions. In addition to its three priority disease areas—Gastroenterology and Inflammation, Neuroscience, and Oncology—plasma-derived therapies and vaccines are also core businesses. The company has a strong presence in the U.S., Europe, and Japan, with overseas markets accounting for approximately 90% of revenue. It has a lineup of flagship products including ENTYVIO (vedolizumab) (for ulcerative colitis and Crohn's disease), Immunoglobulin products (GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU), and TAKHZYRO (lanadelumab) (for hereditary angioedema). Revenue for FY2026 (ending March 2026) was ¥4,505,720 million.
Business Model
The company combines in-house R&D (annual R&D expenses of approximately ¥675,900 million) with external partnerships and licensing to generate high returns from innovative pharmaceuticals during their patent protection period. After launch, lifecycle value is maximized through geographic expansion and additional indications. For plasma-derived products, stable procurement of source plasma and manufacturing technology serve as barriers to entry. The structure aims to shift revenue toward new product groups after patents expire, with Growth & Launch Products accounting for 51% of consolidated revenue (¥2,313,300 million).
Company Strengths
In FY2026 (ending March 2026), ENTYVIO (vedolizumab) generated revenue of ¥958,000 million (21% of consolidated revenue), while Immunoglobulin products (GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU) accounted for ¥790,600 million (18%), with growth and new products combined securing ¥2,313,300 million (51%). ENTYVIO (vedolizumab) is approved in more than 70 countries worldwide, and the spread of its subcutaneous formulation continues to drive expanding demand.
Oveporexton (for narcolepsy), rusfertide (for polycythemia vera), and zasocitinib (for psoriasis and other indications) have each achieved favorable results in Phase 3 clinical trials. Oveporexton has received FDA Priority Review designation, with a PDUFA target date set for Q3 FY2026 (calendar). Each of these products is said to have multi-billion-dollar revenue potential, positioning them as the core drivers of next-generation growth.
Immunoglobulin products (GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU) recorded revenue of ¥790,600 million in FY2026 (ending March 2026), up +4.3% AER year on year. A stable human plasma procurement system combined with a product line offering multiple formulations and routes of administration (intravenous and subcutaneous) forms a barrier to competitive entry.
ENVALITH's Perspective
Performance Trend
Revenue was ¥4,505,720 million (down 1.7% YoY on an AER basis), the first revenue decline in five years. The main driver was a sharp decline of ¥151.5 billion in Neuroscience due to generic erosion of VYVANSE/ELVANSE (lisdexamfetamine). Gastroenterology, Plasma-Derived Therapies, Oncology and other areas maintained revenue growth. Operating profit was ¥6,217 million (versus ¥342,586 million in the previous fiscal year), down 98.2%. The main cause was the recording of a ¥403.5 billion provision for the AMITIZA antitrust litigation, which pushed up other operating expenses to ¥559.0 billion. Net loss attributable to owners of the company was ¥152,390 million, a sharp deterioration from the ¥107,928 million profit recorded in the previous fiscal year. Meanwhile, Core performance improved, with Core EPS of ¥517 (up 5.2% on an AER basis), widening the gap between the underlying strength of the core business and reported financial results. For FY2027 (ending March 2027), the company forecasts revenue of ¥4,640,000 million (up 3.0%) and operating profit of ¥420,000 million. The main factors behind the recovery are the end of VYVANSE amortization and the absence of a recurring litigation provision.
Growth Strategy
Achieving mid-30% Core operating margin through new product launches, late-stage pipeline advancement, and cost savings exceeding ¥200 billion
The company aims to launch multiple new drugs, including oveporexton, rusfertide, and zasocitinib, within the next 12 months. All three products have already achieved favorable results in Phase 3 clinical trials in 2025. Subject to regulatory approval, these are positioned as next-generation core products with multi-billion US dollar revenue potential.
The company targets annualized cost savings of over ¥200 billion by FY2028, driven by organizational optimization, business process standardization, and the use of AI/digital technologies. The savings will be allocated to new product launch investments, late-stage pipeline development costs, and technology investments. In FY2025, company-wide efficiency programs achieved SG&A and R&D expense savings exceeding plan.
Over the medium to long term, the company aims to transition revenue contribution from its maturing existing portfolio (including VYVANSE/ELVANSE (lisdexamfetamine)) to new core products (oveporexton, rusfertide, zasocitinib, etc.). By growing revenue while maintaining expense discipline, the company targets improving the Core operating margin from the low-30% range to the mid-30% range. It will also pursue the target Adjusted Net Debt/Adjusted EBITDA ratio of 2.0x in parallel.
The company maintains a progressive dividend policy of increasing or maintaining the annual dividend per share each year: ¥200 in FY2025 and a forecast of ¥204 in FY2026. Using Adjusted Free Cash Flow of ¥684.5 billion (FY2025 actual) as a source of funds, the company intends to balance growth investment, dividends, and debt reduction through disciplined capital allocation. The final financial impact of the AMITIZA litigation is stated to result in no change to the FY2026 earnings forecast or dividend forecast.
Last updated: July 19, 2026